Menu
Immuno Oncology Europe
Immuno Oncology Europe
Immuno-Oncology Summit Europe
-歐洲癌症免疫高峰會-
日期:2017年3月20-24日
地點:英國倫敦,Hilton Canary Wharf

大會議程

Novel Approaches for Cancer   Immunomodulatory Approaches  Combination Immunotherapy

短期會議

3月21日 18:30-21:30

Dinner SC1:
New Directions in Cancer Immunotherapy (癌免疫療法新方向)

Dinner SC2:
CAR T and TCR Manufacturing Challenges to Anticipate and Overcome: Focus on How, Where, and Cost Factors (CAR-T及TCR製造相關課題預測及克服:方法、場所、費用要因)
 

Featured Presenters

Roy BaynesRoy D. Baynes, M.D., Ph.D.
Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp & Dohme

Zelig EshharZelig Eshhar, Ph.D.
Chair, Cancer Immunotherapy, Research and Development, Sourasky Medical Center, Tel Aviv

David FeltquateDavid Feltquate, M.D., Ph.D.
Vice President, Oncology Development, Bristol-Myers Squibb

Dario NeriDario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich

Andy_SewellAndrew Sewell, Ph.D.
Professor, Institute of Infection & Immunity, Cardiff University School of Medicine

Robert WilkinsonRobert W. Wilkinson, Ph.D.
Director, Oncology Research, MedImmune Ltd.

 


關於本高峰會

承接上屆高峰會的成功經驗,Immuno-Oncology Summit Europe在2017年也將繼續舉行。本屆高峰會將跟2016年一樣,在倫敦的中心地帶舉行,是世界各國研究人員及業界相關人士不可錯過的重要活動。

本高峰會為期一週,將針對最新研究成果展開熱烈的討論。在癌症治療新方法的議程中,將聚焦於包含CAR-T技術在內的T細胞及受體、雙特異性抗體、臨床前模型、標的及先導化合物的選定等主題。免疫調節療法議程中,將深入討論檢查點抑制劑、活化受體的關聯、NK、巨噬體及樹狀細胞的活化、Fc工程技術、細胞激素療法、溶瘤疫苗等主題在各領域研究的進展狀況。此外,在併用免疫療法的議程中,除了併用療法的設計與策略相關演講之外,也將介紹臨床前研究與臨床研究的最新情報。


上屆高峰會的參加者之聲

"Very stimulatory meeting in an exciting field. Great mix of complementary presentations."

Kerry Chester, Ph.D., Professor, UCL Cancer Institute

"I believe you managed to collate an excellent mix of speakers spanning the most critical aspects of immune oncology, providing an informal forum for discussions between leaders in the field and new investigators coming from both academia and industry."

Björn Frendéus, Ph.D., Chief Scientific Officer, BioInvent International AB

"The content of the meeting was highly relevant and up to date."

Khaterech Ahmadi, Executive Director, MSD-Merck

"The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented."

Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.

Choose your language
Chinese
Japanese
Korean
English

Catalog



免費電子郵件通知服務
免費電子郵件通知服務